Bill Sponsor
House Bill 2063
115th Congress(2017-2018)
Opioid PACE Act of 2017
Introduced
Introduced
Introduced in House on Apr 6, 2017
Overview
Text
Introduced in House 
Apr 6, 2017
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Apr 6, 2017)
Apr 6, 2017
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
H. R. 2063 (Introduced-in-House)


115th CONGRESS
1st Session
H. R. 2063


To amend the Controlled Substances Act to require certain training as a condition of registration to prescribe or dispense opioids for the treatment of pain or pain management, and for other purposes.


IN THE HOUSE OF REPRESENTATIVES

April 6, 2017

Mr. Schneider introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To amend the Controlled Substances Act to require certain training as a condition of registration to prescribe or dispense opioids for the treatment of pain or pain management, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Opioid Preventing Abuse through Continuing Education Act of 2017” or the “Opioid PACE Act of 2017”.

SEC. 2. Practitioner education.

(a) Training requirements.—

(1) IN GENERAL.—Section 303(f) of the Controlled Substances Act (21 U.S.C. 823(f)) is amended—

(A) by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively;

(B) by striking “(f) The Attorney General” and inserting “(f)(1) Subject to paragraph (2), the Attorney General”; and

(C) by adding at the end the following:

“(2) (A) To be registered under paragraph (1) to prescribe or otherwise dispense opioids for the treatment of pain, or pain management, a practitioner (other than a hospital, a pharmacy, a pharmacist, or a veterinarian) shall comply with the 12-hour training requirement of this paragraph at least once during each 3-year period.

“(B) The training requirement of this paragraph is that the practitioner has completed not less than 12 hours of training (through classroom situations, seminars at professional society meetings, electronic communications, or otherwise) with respect to—

“(i) pain management treatment guidelines and best practices,

“(ii) early detection of opioid addiction, and

“(iii) the treatment and management of opioid-dependent patients,

that is provided by the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, the American Psychiatric Association, the American Academy of Pain Management, the American Pain Society, the American Academy of Pain Medicine, the American Board of Pain Medicine, the American Society of Interventional Pain Physicians, or any other organization that the Secretary determines is appropriate for purposes of this paragraph.”.

(2) FUNDING.—The Drug Enforcement Administration shall fund the enforcement of the requirements specified in section 303(f)(2) of the Controlled Substances Act (as added by paragraph (1)) through the use of a portion of the licensing fees paid by controlled substance prescribers under the Controlled Substances Act (21 U.S.C. 801 et seq.).

(b) Establishment of training modules.—

(1) IN GENERAL.—The Secretary of Health and Human Services shall establish or support the establishment of one or more training modules to be used to meet the training requirement under section 303(f)(2) of the Controlled Substances Act (as added by subsection (a)(1)).

(2) ELIGIBLE ENTITIES.—To be eligible to receive support under paragraph (1), an entity shall be—

(A) one of the organizations listed in subparagraph (B) of section 303(f)(2) of the Controlled Substances Act (as added by subsection (a)(1)); or

(B) any other organization that the Secretary determines is appropriate to provide training under such section 303(f)(2).

(3) AUTHORIZATION OF APPROPRIATIONS.—To carry out this subsection, there is authorized to be appropriated $1,000,000 for each of fiscal years 2018 through 2022.